Navigation Links
Diabetes and cancer: A shared biological basis
Date:9/29/2011

Contrary to what you might think, cancer and diabetes appear to have some biology in common. According to a report in the September 30th issue of the Cell Press journal, Cell, a pathway that initially drew attention for its role in embryonic stem cells and cancer also influences the odds that mice develop or resist diabetes.

Mice with high levels of the cancer-promoting proteins Lin28a or Lin28b become more sensitive to insulin and less prone to diabetes when on a high-fat diet, the new study shows.

"This highlights the overlap in the biology of these disorders," said George Daley of Harvard Medical School. "It may be the same kinds of metabolic shifts that allow cancer cells to grow are also related to [whole-body] glucose metabolism."

In fact, there were clues about such a connection, but "no obvious mechanism," he says. For instance, studies have shown that cancer cells within a tumor are able to grow more rapidly by shifting the way they use glucose. Genome-wide association studies for type 2 diabetes have also pinpointed several susceptibility genes with known links to cancer or the cell cycle.

Daley's team, including first authors Hau Zhu and Ng Shyh-Chang, had noticed earlier that an immature form of the microRNA (tiny bits of RNA that silence genes by targeting messenger RNA) known as let-7 is abundant in stem cells. "It allows stem cells to be stem cells," Zhu says.

Let-7 is also important in preventing cancer, Zhu explained, and its activity is blocked by the cancer-promoting RNA-binding protein Lin28. Lin28 is also known as an ingredient that can help turn skin cells into embryonic stem cell-like cells.

"Mice with too much Lin28 grow really large," Zhu said based on their earlier work. "They are giant mice and they soak up glucose really efficiently." The new study shows that Lin28 transgenic mice are also resistant to diabetes and obesity. That resistance holds even as the mice grow older, said Shyh-Chang.

Mice lacking Lin28a or that have increases in let-7 become insulin resistant and have impaired glucose tolerance. These metabolic changes occurred in part through effects linked to the insulin-PI3K-mTOR pathway, which is important in cancer and basic metabolism.

Importantly, the researchers also found that let-7 acts on many genes with apparent links to type 2 diabetes and glucose control in humans. This may prove to be good news for those in search of new ways to tackle complex conditions like diabetes, which have many genetic drivers, each with relatively small effects.

"MicroRNAs touch multiple targets in subtle ways," Shyh-Chang said. "Our findings suggest that let-7 and perhaps other microRNAs may help to unify the picture of how type 2 diabetes develops."


'/>"/>

Contact: Lisa Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Neighborhood socioeconomic status and diabetes
2. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
3. International Diabetes Federation awards $2 million to 9 global diabetes research projects
4. Diabetes drug ups risk for bone fractures in older women
5. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
6. Fishy Smell May Keep Patients From Diabetes Drug
7. Small Increase in Diabetes Risk Noted in Statin Patients
8. FDA Approved Diabetes Drug Despite Hints at Cancer Risk
9. Remove Diabetes Drug Avandia From Market: FDA Reports
10. Remove Diabetes Drug Avandia From Market: FDA Documents
11. Excessive Weight Gain During Pregnancy Raises Gestational Diabetes Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: